Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02985710 · ClinicalTrials.gov registry record · NA
Assessment of Small Fiber Neuropathy in Rare Diseases Using Sudoscan
A NA study of Fabry Disease and Mitochondrial Disease, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 102
- Enrollment target
- 1
- Study location
NCT02985710 is a NA study of Fabry Disease and Mitochondrial Disease that has completed, run by Massachusetts General Hospital. The registered enrollment target is 102 participants, below the 540-participant average among 32 other Fabry Disease trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02985710, a NA study of Fabry Disease and Mitochondrial Disease, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 102 participants
- Enrollment target
- 1
- Study location
Study Summary
Sudoscan™ (Impeto Medical, Paris France) uses electrochemical skin conductance as a novel noninvasive method to detect sudomotor dysfunction. Several small studies have recently shown that Sudoscan use in the assessment of small fiber polyneuropathy (in diabetes mellitus) can be performed non-invasively, quickly and effectively. The investigators aim to study the use of Sudoscan in rare disease condition associated with small fiber polyneuropathy.
Conditions Studied
Interventions
- PROCEDURE Skin biopsy
- DEVICE Sudoscan
- PROCEDURE QSART
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2016-08 |
| Est. Completion | 2020-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02985710
The ClinicalTrials.gov registry entry for NCT02985710 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 540-participant average among 32 other Fabry Disease trials with a reported enrollment target (81% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Fabry Disease appearing as the primary indexed condition, and to 3 interventions - of which Skin biopsy is the first listed.
NCT02985710 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02985710 about?
NCT02985710 is a clinical study titled "Assessment of Small Fiber Neuropathy in Rare Diseases Using Sudoscan". Sudoscan™ (Impeto Medical, Paris France) uses electrochemical skin conductance as a novel noninvasive method to detect sudomotor dysfunction. Several small studies have recently shown that Sudoscan use in the assessment of small fiber polyneuropathy (in diabetes mellitus) can be performed non-invasi...
What is the current status of trial NCT02985710?
This trial is currently completed. It is a NA study. The enrollment target is 102 participants. The study started on 2016-08. Estimated completion is 2020-08.
What conditions does trial NCT02985710 study?
This clinical trial studies the following conditions: Fabry Disease, Mitochondrial Disease, Ehlers-Danlos Syndrome, Small Fiber Neuropathy.
What interventions are being tested in trial NCT02985710?
The interventions under investigation include: Skin biopsy (PROCEDURE), Sudoscan (DEVICE), QSART (PROCEDURE).
Who is sponsoring clinical trial NCT02985710?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02985710 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fabry Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
RECRUITING
-
Natural History and Structural Functional Relationships in Fabry Renal Disease Treatment Outcomes(Changes)in Fabry Renal Disease Study
RECRUITING
-
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
RECRUITING · Phase 3
-
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
RECRUITING · Phase 2
-
A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients
RECRUITING
-
A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.